Lead Sponsor

AstraZeneca

Collaborators

Age

All ages

Sex

FEMALE

Healthy Volunteers

No

•Postmenopausal women with hormone sensitive early breast cancer.
•Documented decision of treatment with anastrozole which will start in 13 weeks according to current SmPC OR current treatment with anastrozole according to current SmPC, that has not exceeded thirteen weeks before enrollment.
•Subjects who accept to use MEMS® monitors to automatically compile their drug dosing histories.

•Concomitant or previous use of adjuvant tamoxifen, letrozole or exemestane for the current tumour.
•Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff or staff at the study site).
•Participation in another clinical study with an investigational product during the last 3 months.